1st European Society of Pathology Academy

23 – 26 June 2018
Waterloo, Belgium

www.esp-pathology.org
Scientific Programme

- Saturday, 23 June 2018 .......... 4
- Sunday, 24 June 2018 .......... 4
- Monday, 25 June 2018 .......... 5
- Tuesday, 26 June 2018 .......... 5

Invited Speakers

- Dina G. Tiniakos ................... 6
- Peter Schirmacher ................ 6
- Fred T. Bosman ................... 7
- Radek Špišek ....................... 7
- Michael Hummel ................... 8
- Holger Moch ....................... 8
- Fátima Carneiro ................... 9
- Pierre Bedossa .................... 9
- Gert G.G.M. Van den Eynden .... 10
- Ruedi Aebersold ................. 10
- Irene Esposito .................... 11
- Han van Krieken .................. 11
- Lars Zender ....................... 12
- Nektarios Tavernarakis .......... 12
- Natalio Krasnogor ............... 13
- Aleš Ryška ....................... 13
- Manel Esteller .................... 14
- Marco Santucci ................... 15
- Aurelio Ariza ..................... 15
### Scientific Programme

#### Saturday, 23 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Welcome and Lunch</td>
</tr>
<tr>
<td>09:00</td>
<td>Keynote Lecture: Proteomics</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00</td>
<td>Translational research: what does it mean?</td>
</tr>
<tr>
<td>12:00</td>
<td>The role of pathology in hereditary and rare cancers</td>
</tr>
<tr>
<td>13:00</td>
<td>mitochondrial dysfunction, challenges and opportunities</td>
</tr>
<tr>
<td>14:00</td>
<td>Integrating pathology into epidemiology: challenges and opportunities</td>
</tr>
<tr>
<td>15:00</td>
<td>Correlation of tumour-stroma ratio and clinical outcome in patients with head and neck squamous cell carcinoma after adjuvant radiotherapy</td>
</tr>
<tr>
<td>16:00</td>
<td>Senescent carcinomas: microenvironment and immune responses</td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

#### Sunday, 24 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>RANKL alternatively aggressive properties of ER-negative breast cancer by inhibiting NF-kB activation and ESRI signaling</td>
</tr>
<tr>
<td>09:00</td>
<td>Six hormon receptors and BIM: role of BIM in estrogen receptor-negative breast cancers</td>
</tr>
<tr>
<td>10:00</td>
<td>Molecular variability in uterine smooth muscle tumours</td>
</tr>
<tr>
<td>11:00</td>
<td>Molecular pathology and morphology: how to make it work together?</td>
</tr>
<tr>
<td>12:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>13:00</td>
<td>Translational research: what does it mean?</td>
</tr>
<tr>
<td>14:00</td>
<td>The role of pathology in hereditary and rare cancers</td>
</tr>
<tr>
<td>15:00</td>
<td>mitochondrial dysfunction, challenges and opportunities</td>
</tr>
<tr>
<td>16:00</td>
<td>Integrating pathology into epidemiology: challenges and opportunities</td>
</tr>
<tr>
<td>17:00</td>
<td>Correlation of tumour-stroma ratio and clinical outcome in patients with head and neck squamous cell carcinoma after adjuvant radiotherapy</td>
</tr>
<tr>
<td>18:00</td>
<td>Senescent carcinomas: microenvironment and immune responses</td>
</tr>
<tr>
<td>19:30</td>
<td>How to do meaningful research with little resources?</td>
</tr>
<tr>
<td>20:00</td>
<td>Dinner with Faculty</td>
</tr>
</tbody>
</table>

---

### Scientific Programme

#### Monday, 25 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Rule of MUC1 in kidney disease</td>
</tr>
<tr>
<td>09:00</td>
<td>Pathological evaluation of PD-L1 in urothelial cancers</td>
</tr>
<tr>
<td>10:00</td>
<td>The European Research Council (ERC) programme and funding opportunities</td>
</tr>
<tr>
<td>11:00</td>
<td>Pathology: a being disrupted by Data Integration, AI &amp; funding opportunities</td>
</tr>
<tr>
<td>12:00</td>
<td>The importance of monitoring</td>
</tr>
<tr>
<td>13:00</td>
<td>Cancer epigenetics: from knowledge to applications</td>
</tr>
</tbody>
</table>

#### Tuesday, 26 June 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Role of MUC1 in kidney disease</td>
</tr>
<tr>
<td>09:00</td>
<td>Pathological evaluation of PD-L1 in urothelial cancers</td>
</tr>
<tr>
<td>10:00</td>
<td>The European Research Council (ERC) programme and funding opportunities</td>
</tr>
<tr>
<td>11:00</td>
<td>Pathology: a being disrupted by Data Integration, AI &amp; funding opportunities</td>
</tr>
<tr>
<td>12:00</td>
<td>The importance of monitoring</td>
</tr>
<tr>
<td>13:00</td>
<td>Cancer epigenetics: from knowledge to applications</td>
</tr>
</tbody>
</table>

---

### Social activity

#### Dinner with Faculty

---

### Colour Legend

- **Keynote Lecture**
- **Scientific Topic**
- **General Topic**
- **Selected participants**
- **Research Project**
Dina G. Tiniakos

Dr. Dina Tiniakos is President of the European Society of Pathology (2017–2019). She is Consultant Histopathologist and Assoc. Professor, Medical School, National & Kapodistrian University of Athens, Greece and Senior Lecturer, Institute of Cellular Medicine, Medical School, Newcastle University, UK.

She specialized in hepatobiliary pathology at the Royal Free Hospital, London, UK, Royal Victoria Infirmary, Newcastle upon Tyne, UK and Saint Louis University Hospital, Saint Louis, MO, USA. Dr. Tiniakos is an invited member of the International Liver Study Group “Gnomes” and the Laennec Liver Pathology Society.

Her main research interests are fatty liver disease and hepatocarcinogenesis but she has also published in other areas of liver, gastrointestinal and tumour pathology. She is co-investigator in several EU (EPOS, LITMUS) and UK Medical Research Council (MRC) funded research projects and she is Lead, Research Subcommittee, UK-Liver Pathology Group. She has authored/co-authored >130 peer-reviewed scientific articles and chapters in textbooks of liver pathology and histology. Dr Tiniakos is Training Lead, Newcastle Molecular Pathology Node and co-module leader in the postgraduate programme “Clinical and Health Sciences with Molecular Pathology”, Newcastle University, UK.

Dr. Tiniakos is Associate Editor of “Histopathology”, serves as Editorial Board member of “Liver International”, is reviewer for all major hepatology, gastroenterology and pathology journals, and external assessor for European research grant awarding bodies. She is member of the Executive Board of the International Quality Network for Pathology and the Equality & Diversity Taskforce of United European Gastroenterology.

Fred T. Bosman

Fred Bosman, (1944, the Netherlands), studied Medicine at the University of Leiden (MD 1971), where he also earned his PhD degree (in cytogenetics, 1976) and trained as a pathologist. He was staff pathologist at the University of Leiden (1975–1981), lecturer at the University of Surinam (1974–1975), Professor and chair of Pathology at the Faculty of Medicine of the University of Maastricht (1981–1990) and at the Faculty of Medicine of the Erasmus University in Rotterdam (1990–1995), Director of the University Institute of Pathology and Professor of Pathology at the University Medical Center (CHUV) of Lausanne in Switzerland (1995–2009), now emeritus.

Fred Bosman’s research activities (combining diagnostic and experimental pathology) focused on the biology of digestive tract cancer, notably Barrett’s esophagus and colorectal cancer, with a strong emphasis on the development of molecular diagnostics. He has written over 350 original publications and over 50 book chapters (H-index 80). Fred Bosman was member of the Editorial Board of the Dutch Medical Journal (and president of its Society). He is member of the Editorial Board of several international journals in the fields of Pathology and Histochemistry (former Associate Editor of the Journal of Pathology and emeritus Editor in Chief of Virchows Archiv, European Journal of Pathology). He was one of the Editors of the Dutch textbook ‘Oncology’ and of the Dutch textbook ‘Pathology’. He was Series coeditor of the 4th edition of the WHO Series ‘Classification of Human Tumours’, the international standard for Tumour classification, and co-editor of the Volume on Tumours of the Digestive Tract. He is Section Editor ‘Specific types of cancer’ for Elsevier’s Encyclopedia of Cancer.

Radek Špíšek

Graduated from the 1st Faculty of Medicine of Charles University in Prague, and then studied for and received his PhD in immunology. Between 2000 and 2002, he worked at Institute de Biologie de Université de Nantes in France. He spent three years (2005–2007) in the team led by Professor Ralph Steinman, a medicine and physiology Nobel laureate, at the Laboratory of Cellular Physiology and Immunology/Center for Immunology and Immune Diseases, Rockefeller University, New York.

In his scientific efforts he focuses on tumor immunology and tumor immunotherapy. He is a Professor at Charles University’s 2nd Faculty of Medicine. He has received postgraduate clinical certification in pediatrics and in allergology and clinical immunology.
**Michael Hummel**

Prof. Dr. Michael Hummel is head of the molecular diagnostics at the Institute of Pathology (Charité, Berlin) and a longstanding researcher with a scientific topic for molecular mechanisms in malignant lymphoma (more than 350 high ranking publications). In addition he is the director of the central biobank at the Charité and the Berlin Institute of Health (BIH). Furthermore he is Director of the German Biobank Node and Coordinator of the German Biobank Alliance. In this function he is responsible for the coordination and harmonization of the national biobanking activities and for the representation of the German biobank community at the European level in the frame of the biobanking infrastructure BBMRI-ERIC.

**Holger Moch**

Holger Moch, MD is Professor of Pathology at the University Zurich and Chairman of the Institute for Pathology and Molecular Pathology, University Hospital Zurich, Switzerland since 2004. Holger Moch is board certified in Pathology and in Molecular Pathology. He graduated from Humboldt University Berlin (Charité), Germany and received his MD in 1988. Following graduation, he was a resident at the Institute for Pathology, Charité Berlin and at the Institute for Pathology, University Basel, Switzerland. He was a research fellow in the Division of Molecular Cytometry, Department of Laboratory Medicine, University of California San Francisco; USA and a visiting fellow at Harvard Medical School, Department of Pathology, Massachusetts General Hospital Boston, Massachusetts, USA. In 2001, he was promoted to Associate Professor of Pathology (Titularprofessor) of the University Basel, Switzerland.

Dr. Moch developed a robust translational research program to understand the molecular background of urogenital tumors. His work is described in more than 500 peer-reviewed papers (H-Index 80 in June 2018) and he edited the 2016 WHO “blue book” World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs and is now an editorial board standing member of the WHO Classification of Tumours (5th Edition). He is associate member of the Department of Biology at the Swiss Federal Institute of Technology (ETH) and member of the German National Academy of Science Leopoldina and the Swiss Academy of Medical Sciences. Holger Moch is president-elect of the European Society of Pathology (ESP).

**Fátima Carneiro**

Fátima Carneiro is Full Professor of Pathology and Head of the Unit of Pathology (Medical Faculty of the University of Porto), Head of Department of Anatomic Pathology (Centro Hospitalar São João) and Senior Researcher at Ipatimup/i3S. She is Past President of the European Society of Pathology (ESP), Chair of the Advisory Board of the ESP, Coordinator of the Portuguese Network of Tumour Banks, council member of the International Gastric Cancer Association (IGCA), Fellow of the European Academy of Cancers Sciences (EACS) and President of the National Academy of Medicine (Portugal). She was Delegate of Portugal to the Committee for the FP7 specific programme “Cooperation” and is a member of the Scientific Advisory Board of the ERA-NET on Translational Cancer Research (TRANSCAN). Co-author of about 350 peer-reviewed papers/book chapters (“h factor”: 62; Scopus, accessed on May 31, 2018) and chapters in books issued by IARC ("Pathology & Genetics of Tumours of the Digestive Tract", 3nd Edition, 2000; “Tumours of the Digestive System”, 4th Edition, 2010; World Cancer Report 2014).

She was one of the Editors of the WHO Blue Book on “Tumours of the Digestive System”, 4th Edition, and section Editor of the Encyclopedia of Pathology. She is a standing member of the WHO Blue Books Editorial Board (5th Edition of the WHO Classification of Tumours series).

Her main field of interest is gastrointestinal and liver pathology and her research is directed towards the understanding of the etiopathogenesis of gastric cancer and the molecular basis of gastric carcinoma development.

**Pierre Bedossa**

Pierre Bedossa is former Professor of Pathology at the University Paris-Diderot and served as Head of the Department of Pathology, Physiology, Nuclear Medicine and Imaging at the academic hospitals of Paris Nord-Val de Seine, France. His expertise is liver pathology with longstanding interest in clinical and preclinical research. He was the leader of several European liver pathology consortium (METAVIR, FLIP Pathology consortium), currently involved in several EU funded grants (FLIP, EPOS, LITMUS) and published more than 400 articles in peer-reviewed journals. Pierre Bedossa is also the central pathologist for clinical trials, including several ongoing international Phase 3 and Phase 2B clinical trials in liver diseases.

He is Past President of the European Society of Pathology and founder and CEO of LIVERPAT, a company dedicated to services for biotechnology and pharmaceutical companies in the field of clinical research.
Gert G.G.M. Van den Eynden

Gert G.G.M. Van den Eynden, MD, PhD, is a surgical pathologist, Vice-Head of the Department of Pathology and Cytology of Gasthuiszusters van Antwerpen (GZA) and post-doctoral researcher/consultant pathologist at the Molecular Immunology Unit of the Jules Bordet Institute. He earned his medical degree (2003) and PhD (2008) at Antwerp University and did his residency in pathology at Antwerp University Hospital.

Dr. Van den Eynden’s primary field of interest is breast cancer. Started in the field of angiogenesis and lymphangiogenesis, the last 5 years the main focus of his research has been in the emerging field of onco-immunology and immuno-pathology. As a research pathologist he has extensive experience with the development and assessment of tissue-based immuno-oncological biomarkers in solid tumours. He is involved in several national and international breast cancer research projects, such as the ICGC Breast Cancer Working group and the International Immuno-Oncology Bioraditory Working Group. He has worked as a research pathologist in several clinical trials. Another field of interest of Dr. Van den Eynden is digital pathology and the use of computational pathology and artificial intelligence in the field of pathology.

Dr. Van den Eynden is a member of several professional organizations and currently serves as the secretary of the Breast working group of the Belgian Society of Pathology. He is a member of the International Immuno-Oncology Working Group and he is a member of EQRC’s pathobiology group and co-chairs its biorepository and biobanking working group.

Ruedi Aebersold

Ruedi Aebersold is a Swiss and Canadian scientist trained as a cell biologist at the Biocenter of the University of Basel. He completed his education at the California Institute of Technology. He holds an appointment as Professor at the ETH (Swiss Federal Institute of Technology) Zurich, with a joint appointment at the University of Zurich, Switzerland and serves as chair of the Biology Department at ETH. Before he was on the faculties of the Universities of British Columbia and Washington and co-founded the Institute for Systems Biology in Seattle, with Lee Hood and Alan Adema. He participates as a member of Scientific Advisory Boards for a number of academic and private sector research organizations and has served as senior editor for the journals Molecular and Cellular Proteomics and Molecular Systems Biology. He has co-founded several companies and holds several public service appointments.

The research focus of his group is the proteome. The group has pioneered several important and widely used developments in proteomics, including stable isotope based proteome quantification; open access/open source software and statistical tools supporting proteomic analyses; targeted proteomics for the generation of accurately quantitative, reproducible datasets; and chemical cross linking/mass spectrometry for the analysis of proteins in their cellular context. The work has been recognized with numerous awards and prizes. More than 40 trainees of the group have reached faculty status at leading research institutions in the US, Canada, Australia, Europe and China.

Irene Esposito

Professor of Pathology and Director, Institute of Pathology, Heinrich-Heine University & University Hospital of Duesseldorf, Germany

Irene Esposito is Full Professor of Pathology and since 2015 Head of the Institute of Pathology at the University Hospital of Duesseldorf, Germany. She obtained her MD in 1997 at the University of Pisa, Italy, where she also completed her training in Pathology. After moving to Germany in 2003, she worked as consultant at the Institute of Pathology of the University of Heidelberg (2003 – 2007), where she became Assistant Professor in 2007. After that, she moved to Munich, where she became Head of the Mouse Pathology Unit at the Helmholtz Zentrum in Neuherberg (2008-2010) performing mouse phenotyping at the German Mouse Clinic. In 2010 she was appointed as Associate Professor of Tumor Pathology at the Institute of Pathology of the Technische Universitaet of Munich and in 2011 she became Vice-Director of the Institute. After a short period as Director of the Institute of Pathology of the Medical University of Innsbruck, Austria, she was appointed at the Heinrich Heine University of Duesseldorf and moved back to Germany, where she now lives with her family and her two daughters. Prof. Esposito is an expert in hepato-pancreatico-biliary, gastrointestinal and neuroendocrine pathology. Her scientific interests focus on pancreatico-biliary carcinogenesis and on experimental, comparative and surgical pathology of pancreateo-biliary neoplasms.

Han van Krieken

Han van Krieken is a pathologist with special expertise in the fields of hematopathology and the pathology of the gastrointestinal tract. He was professor for tumor pathology since 1999 and has kept from 2004–2015 the chair of pathology and was head of the department of pathology at the Radboud University Nijmegen Medical Centre. In Nijmegen, from 2009 on he was the chairman of the Radboud University Centre for Oncology, which evolved in 2015 the Radboudumc Centre for Oncology and had the 50% position as chairman until he became Rector Magnificus of the Radboud University in May 2016.

He was the treasurer/secretary of the European Association for Haematopathology (2000–2008; treasurer 2003-2011) and the President of the European Society of Pathology (ESP) (2013–2015). Furthermore he was the chairman of the working party for pathology of the digestive system of the ESP (2003–2007) and directs the external quality assurance program since 2009.

He is (co)author of more than 500 papers in peer reviewed journals, has written chapters in books on pathology and oncology, is chief editor of a Dutch Textbook on oncology and the Encyclopedia of Pathology and serves on the editorial board of the American Journal of Surgical Pathology, was managing editor of Virchows Archiv (2009–2015) and the Chief editor of the Journal of Hematopathology (2007–2017). Since 2011 he is member of the German Academy of Sciences Leopoldina and since 2014 member of the Academia Europaea and Honorary Fellow of the Royal College of Pathology.
Nektarios Tavernarakis

Nektarios Tavernarakis is the Chairman of the Board of Directors at the Foundation for Research and Technology-Hellas (FORTH), Research Director at the Institute of Molecular Biology and Biotechnology (IMBB), and Professor of Molecular Systems Biology at the Medical School of the University of Crete, in Heraklion, Greece. He is the Director of the Graduate Program on Bioinformatics at the Medical School of the University of Crete, and is also heading the Neurogenetics and Ageing laboratory of IMBB. He is an elected member of the Scientific Council of the European Research Council (ERC), the European Molecular Biology Organization (EMBO), and Academia Europaea. He has also served as the Director of the Institute of Molecular Biology and Biotechnology. He earned his Ph.D. degree at the University of Crete, and trained as a postdoctoral researcher at Rutgers University in New Jersey, USA. His research focuses on the molecular mechanisms of necrotic cell death and neurodegeneration, the interplay between cellular metabolism and ageing, the mechanisms of sensory transduction and integration by the nervous system, and the development of novel genetic tools for biomedical research. He has received several notable scientific prizes, including two ERC Advanced Investigator Grants, and an innovation-supporting ERC Proof of Concept Grant. He is also the recipient of the EMBO Young Investigator award, the Alexander von Humboldt Foundation, Friedrich Wilhelm Bessel research award, the Bodossaki Foundation Scientific Prize for Medicine and Biology, the Empererion Foundation Academic Excellence Prize, the Research Excellence award of the Foundation for Research and Technology-Hellas, the BioMedical Research Award of the Academy of Athens, the Galken Scientific Research Award, and the Helmholtz International Fellow Award.

Lars Zender

Lars Zender, M.D., is Head of the Department for Internal Medicine VIII and the Department of Végetative and Clinical Physiology at University Hospital Tuebingen, Germany. Lars Zender’s work especially focuses on the identification of new cancer genes involved in liver cancer development. He developed novel mosaic (chimaeric) liver cancer mouse models, which allow for high throughput functional genomic analyses. Together with a limited number of other laboratories worldwide, Lars Zender’s group has the expertise to conduct stable RNA interference screens for the identification and validation of new cancer genes directly in vivo.

Another key aspect in the scientific work of Lars Zender is his work on cellular senescence. In particular, the Zender laboratory is studying the senescence-associated secretory phenotype and how senescent tumour cells and pre-cancerous cells are recognized and cleared by the immune system. Recent work from Lars Zender’s laboratory showed that a continuous antigen specific immune clearance of premalignant senescent hepatocytes is crucial for tumour suppression in the liver. He received many awards, including the Gottfried Wilhelm Leibniz Prize of the German Research Foundation (DFG). Lars Zender is holding an ERC Consolidator Grant and is Medical Director of the Phase I Clinical and Scientific Director of the CCC-TS.

Natalio Krasnogor

Prof. Natalio Krasnogor, Professor of Computing Science and Synthetic Biology, directs the Interdisciplinary Computing and Complex Bio-systems (http://iccs.liquidnet.co.uk) research group and is director of Newcastle’s Centre for Synthetic Biology and the Bioeconomy (https://www.ncl.ac.uk/csbibio/). Krasnogor held an EPSRC Leadership Fellowship in Synthetic Biology (EP/J004111/1-£1M) and was the overall lead in the EPSRC Synthetic Biology ROADBLOCK (EP/I031642/1, EP/I031812/1, EP/I03157X/£- £.7M) project that involved Newcastle, Nottingham, Sheffield, Warwick and Bradford Universities. He currently is PI for the EPSRC programme grant “Synthetic Portalobomics: Leading the way at the crossroads of the Digital and the Bio Economies” (EP/N031962/1, £.4M + £3M support from industry and Newcastle).

He leads the Computational science strand within Newcastle Molecular Pathology Node (http://www.newcastlepathnode.org.uk/) funded by the UK’s MRC (MR/N005827/1, £.8M).

Krasnogor gave several keynote talks (e.g. IEEE CEC, PPSN, GECCO, IPMU, etc); has >170 publications (H-index 44), with many papers in the top 0.1% and 1% for number of citations in computing science and also papers in Nature Biotech, Nature Chemistry, PNAS, NAR, EMBO Journal, etc. He won several best papers prizes as well as Bronze, Silver and Gold awards of the American Computing Society’s (ACM) HUMIES and ACM’s Impact award.

From 2012 to 2014 he was the Science Director of the European Centre for Living Technologies (Italy) and was distinguishing visiting professor at Ben Gurion University, Israel in 2009 and Weizmann Institute of Science, Israel in 2010, 2012 & 2013, Tel Aviv University, Israel in 2017 and Universidad Nacional de Tucumán, Argentina in 2018.

Aleš Ryška

Graduated at the Charles University, Medical Faculty in Hradec Králové (MD - 1994), Ph.D. in pathology (2001), board certification in pathology (2000). Working at The Fingerland Department of Pathology, Charles University Medical Faculty in Hradec Králové, Czech Republic (full Professor of Pathology - 2007 - to date), Vice-Dean for Student’s Affairs - 2003 - 2010. Currently head of the department.

Member of several scientific societies and editorial boards (International Academy of Pathology - Czech Division - president, Society of Czech Pathologists – president (till 2016), European Society of Pathology - member of the Executive Council (2013–2017), European Society of Pathology – chair of the Education Subcommittee, Czech Oncologic Society – board member, Local Organizing Committee of the 24th European Congress of Pathology in Prague (2012) - chair, Local Organizing Committee of the 25th Pannonia Congress of Pathology (2018) - chair, Editorial board Czech-Slovak Pathology and Forensic Medicine, Editorial board Virchows Archiv - Associate Editor, Editorial board Clinical Oncology.
Manel Esteller

Manel Esteller graduated in Medicine from the Universitat de Barcelona, where he also obtained his Ph.D. degree specialising in molecular genetics of endometrial carcinoma. Dr. Esteller was a Postdoctoral Fellow and a Research Associate at the Johns Hopkins University and School of Medicine, Baltimore, USA where he studied DNA methylation and human cancer. His work was decisive in establishing promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours. From October 2001 to September 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory. Since October 2008, Dr Esteller is the Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Institute for Biomedical Research (IDIBELL) in Barcelona, Leader of the Cancer Epigenetics Group, Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor. His current research is devoted to the establishment of the epigenome and human cancer - cytology, histology and special methods, such as immunohistochemistry, molecular biology, etc. as well as in predictive pathology (detection of markers predicting response to targeted therapy) and quality control in pathology. Principal investigator and co-investigator of 15 research projects.


Invited speaker at multiple national and international meetings (Czech Republic, Slovakia, Germany, Hungary, Portugal, Romania, Serbia, Slovenia, Croatia, Austria, Australia, Poland, Macedonia, Ireland, Bulgaria, Spain, Netherlands, UK, USA). Tutor at the course of European School of Pathology (thyroid gland pathology). Total 1197 records in the SCI, h-index=19.

Marco Santucci

Marco Santucci is Professor of Pathological Anatomy, Head of the Department of Surgery and Translational Medicine and Member of the Academic Senate of the University of Florence.

The work of Marco Santucci was especially focused on cutaneous and head & neck pathology. In particular, concerning skin pathology, major themes of interest were the signaling pathways and receptor systems involved in the pathogenesis of malignant melanoma and the role of tumoral microenvironment in tumor progression, with special emphasis to lymphangiogenesis and tumor associated macrophages. Other major theme of research was represented by primary cutaneous lymphomas. As a founding member of the EORTC Cutaneous Lymphoma Study Group, subsequently named EORTC Cutaneous Lymphoma Task Force, contributed to the discovery of new lymphoma entities and to the identification of clinically relevant classification schemes.

Regarding head & neck pathology, main topics of interest were represented by the inducible nitric oxide synthase (iNOS) expression and the correlation with lymphangiogenesis, vascular endothelial growth factor-C expression and transforming growth factor beta type II receptor in laryngeal neoplasia; the expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head & neck and correlation with p53 status, iNOS activity, and angiogenesis; the immunohistochemical investigation of tumorigenic pathways using tissue microarray analysis and the role of epidermal growth factor receptor expression and gene copy number in sinonasal intestinal-type adenocarcinoma; and the biomolecular characterization of sinonasal intestinal-type adenocarcinoma in leather and woodworkers.

Aurelio Ariza

Aurelio Ariza (1952, Spain) is professor of Pathology at the Autonomous University of Barcelona (UAB) and senior consultant at the Department of Pathology, Hospital Universitari Germans Trias i Pujol (HUGTP), Badalona, Barcelona, Spain. He obtained his MD degree at the University of Seville (1975). After pursuing his anatomic pathology residency training at the Yale-affiliated Hospital of St Raphael, New Haven, Connecticut, during the period 1980-1984, he completed his training with a fellowship in neuropathology and a fellowship in surgical pathology at the Yale-New Haven Hospital (Yale University) during the period 1984-1988. Among others, he has been research coordinator of the HUGTP (1997-2000), research vice dean of the UAB Medical School, and president of the Spanish Society of Pathology (2007-2011). Currently, he is secretary of the European Society of Pathology, Spanish representative to the UEMS Section of Pathology, and president of the National Commission for Anatomical Pathology of the Spanish Ministry of Health. Additionally, he has received the Professional Excellence Award of the Barcelona Medical College (2011) and has been appointed member of the Royal Academy of Medicine of Catalonia (2012). He has been the principal investigator of several neuropathology and tumor pathology projects and has authored or co-authored over 140 peer-reviewed articles. The unveiling of p53 and JC virus interactions in progressive multifocal leukoencephalopathy has constituted one of his favorite research topics. He is co-author of four patents dealing with neurodegenerative diseases.
Contact Details
European Society of Pathology
Rue Bara 6
1070 Brussels, Belgium
www.esp-pathology.org
admin@esp-pathology.org

ESPA Organising Committee
Dina Tiniakos, Greece/United Kingdom
Pierre Bedossa, France
Peter Schirmacher, Germany
Aleš Ryška, Czech Republic
Raed Al Dieri, Belgium
Joerg Maas, Germany